3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma’s in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed.
Eltrombopag olamine is recognized as the world’s first oral small molecule thrombopoietin (TPO) receptor agonist (TPO-RA), capable of engaging with the transmembrane domain of human TPO receptors to initiate signal transduction reactions. This interaction stimulates the proliferation and differentiation of bone marrow megakaryocytes, promoting platelet production and release. Novartis’s Revolade, the originator product, was first approved in the US in 2008 and later in China in 2018 for the treatment of chronic immune (idiopathic) thrombocytopenia (ITP) in adults and children aged six and above unresponsive to glucocorticoids and immunoglobulins, aiming to increase platelet count and reduce or prevent bleeding.
HQ Pharma’s dry suspension dosage form marks the first of its kind in China to be filed for marketing, targeting ITP and severe aplastic anemia (SAA). This innovative product avoids dental caries, boasts improved palatability, and can significantly enhance patient compliance. Its convenience in dosage adjustment and precise administration makes it particularly suitable for children, the elderly, and patients with swallowing difficulties.- Fineline.com
